The CLL comorbidity index in a population-based cohort: a tool for clinical care and research

Emelie C. Rotbain; Max J. Gordon; Noomi Vainer; Henrik Frederiksen; Henrik Hjalgrim; Alexey V. Danilov; Carsten U. Niemann

doi:10.1182/bloodadvances.2021005716

The CLL comorbidity index in a population-based cohort: a tool for clinical care and research

Emelie C. Rotbain, Max J. Gordon, Noomi Vainer, Henrik Frederiksen, Henrik Hjalgrim, Alexey V. Danilov, Carsten U. Niemann^*

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

17 Citationer (Scopus)

12 Downloads (Pure)

Abstract

The chronic lymphocytic leukemia comorbidity index (CLL-CI) is an efficient, CLL-specific tool derived from the Cumulative Illness Rating Scale. The CLL-CI is based on the assessment of the organ systems found to be most strongly associated with event-free survival (EFS) in CLL: vascular, upper gastrointestinal, and endocrine, at the time of initiation of CLL therapy. The CLL-CI categorizes patients into low, intermediate, and high risk groups. In the present study, we have employed the CLL-CI in a population-based cohort comprising 4975 patients with CLL. We demonstrate that CLL-CI retains prognostic significance in this large cohort and is associated with overall survival (OS) and EFS from time of first therapy. Furthermore, CLL-CI associates with OS, EFS, and time to first treatment from diagnosis independently of the CLL International Prognostic Index. These findings support the use of the CLL-CI both in research and in clinical practice.

Originalsprog	Engelsk
Tidsskrift	Blood advances
Vol/bind	6
Udgave nummer	8
Sider (fra-til)	2701-2706
Antal sider	6
ISSN	2473-9529
DOI	https://doi.org/10.1182/bloodadvances.2021005716
Status	Udgivet - 2022

Bibliografisk note

Funding Information:
This work was supported in part by grants from Novo Nordisk Foundation (NNF16OC0019302) (C.U.N.) and Neye Fonden (H.H.). A.V.D. is a Leukemia and Lymphoma Society Clinical Scholar (#2319-19).

Publisher Copyright:
© 2022 by The American Society of Hematology.

Adgang til dokumentet

10.1182/bloodadvances.2021005716Licens: CC BY-NC-ND

FulltextForlagets udgivne version, 876 KBLicens: CC BY-NC-ND

Citationsformater

@article{68007c3b07304abfb72cc90f5ec27f51,

title = "The CLL comorbidity index in a population-based cohort: a tool for clinical care and research",

abstract = "The chronic lymphocytic leukemia comorbidity index (CLL-CI) is an efficient, CLL-specific tool derived from the Cumulative Illness Rating Scale. The CLL-CI is based on the assessment of the organ systems found to be most strongly associated with event-free survival (EFS) in CLL: vascular, upper gastrointestinal, and endocrine, at the time of initiation of CLL therapy. The CLL-CI categorizes patients into low, intermediate, and high risk groups. In the present study, we have employed the CLL-CI in a population-based cohort comprising 4975 patients with CLL. We demonstrate that CLL-CI retains prognostic significance in this large cohort and is associated with overall survival (OS) and EFS from time of first therapy. Furthermore, CLL-CI associates with OS, EFS, and time to first treatment from diagnosis independently of the CLL International Prognostic Index. These findings support the use of the CLL-CI both in research and in clinical practice.",

author = "Rotbain, {Emelie C.} and Gordon, {Max J.} and Noomi Vainer and Henrik Frederiksen and Henrik Hjalgrim and Danilov, {Alexey V.} and Niemann, {Carsten U.}",

note = "Publisher Copyright: {\textcopyright} 2022 by The American Society of Hematology.",

year = "2022",

doi = "10.1182/bloodadvances.2021005716",

language = "English",

volume = "6",

pages = "2701--2706",

journal = "Blood advances",

issn = "2473-9529",

publisher = "American Society of Hematology",

number = "8",

}

TY - JOUR

T1 - The CLL comorbidity index in a population-based cohort

T2 - a tool for clinical care and research

AU - Rotbain, Emelie C.

AU - Gordon, Max J.

AU - Vainer, Noomi

AU - Frederiksen, Henrik

AU - Hjalgrim, Henrik

AU - Danilov, Alexey V.

AU - Niemann, Carsten U.

PY - 2022

Y1 - 2022

N2 - The chronic lymphocytic leukemia comorbidity index (CLL-CI) is an efficient, CLL-specific tool derived from the Cumulative Illness Rating Scale. The CLL-CI is based on the assessment of the organ systems found to be most strongly associated with event-free survival (EFS) in CLL: vascular, upper gastrointestinal, and endocrine, at the time of initiation of CLL therapy. The CLL-CI categorizes patients into low, intermediate, and high risk groups. In the present study, we have employed the CLL-CI in a population-based cohort comprising 4975 patients with CLL. We demonstrate that CLL-CI retains prognostic significance in this large cohort and is associated with overall survival (OS) and EFS from time of first therapy. Furthermore, CLL-CI associates with OS, EFS, and time to first treatment from diagnosis independently of the CLL International Prognostic Index. These findings support the use of the CLL-CI both in research and in clinical practice.

AB - The chronic lymphocytic leukemia comorbidity index (CLL-CI) is an efficient, CLL-specific tool derived from the Cumulative Illness Rating Scale. The CLL-CI is based on the assessment of the organ systems found to be most strongly associated with event-free survival (EFS) in CLL: vascular, upper gastrointestinal, and endocrine, at the time of initiation of CLL therapy. The CLL-CI categorizes patients into low, intermediate, and high risk groups. In the present study, we have employed the CLL-CI in a population-based cohort comprising 4975 patients with CLL. We demonstrate that CLL-CI retains prognostic significance in this large cohort and is associated with overall survival (OS) and EFS from time of first therapy. Furthermore, CLL-CI associates with OS, EFS, and time to first treatment from diagnosis independently of the CLL International Prognostic Index. These findings support the use of the CLL-CI both in research and in clinical practice.

U2 - 10.1182/bloodadvances.2021005716

DO - 10.1182/bloodadvances.2021005716

M3 - Journal article

C2 - 35008098

AN - SCOPUS:85129903802

VL - 6

SP - 2701

EP - 2706

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 8

ER -